EdgarLookup

Definium Therapeutics, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Definium Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($67.27M) Nov 6, 2025
Q2 2025 Jun 30, 2025 ($42.74M) Jul 31, 2025
Q1 2025 Mar 31, 2025 ($23.35M) May 8, 2025
Q3 2025 Sep 30, 2024 ($13.68M) Nov 6, 2025
Q2 2025 Jun 30, 2024 ($5.85M) Jul 31, 2025
Q1 2025 Mar 31, 2024 ($54.40M) May 8, 2025
Q3 2024 Sep 30, 2023 ($17.92M) Nov 7, 2024
Q2 2024 Jun 30, 2023 ($29.13M) Aug 13, 2024
Q1 2024 Mar 31, 2023 ($24.82M) May 8, 2024
Q3 2023 Sep 30, 2022 ($16.49M) Nov 2, 2023
Q2 2023 Jun 30, 2022 ($16.96M) Aug 3, 2023
Q1 2023 Mar 31, 2022 ($18.45M) May 4, 2023
Q3 2022 Sep 30, 2021 ($17.20M) Nov 10, 2022
Q2 2022 Jun 30, 2021 ($45.25M) Aug 11, 2022
Q1 2022 Mar 31, 2021 ($13.76M) May 16, 2022

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($45.67M) Nov 6, 2025
Q2 2025 Jun 30, 2025 ($40.90M) Jul 31, 2025
Q1 2025 Mar 31, 2025 ($32.16M) May 8, 2025
Q3 2025 Sep 30, 2024 ($24.79M) Nov 6, 2025
Q2 2025 Jun 30, 2024 ($24.46M) Jul 31, 2025
Q1 2025 Mar 31, 2024 ($22.20M) May 8, 2025
Q3 2024 Sep 30, 2023 ($21.62M) Nov 7, 2024
Q2 2024 Jun 30, 2023 ($29.18M) Aug 13, 2024
Q1 2024 Mar 31, 2023 ($20.86M) May 8, 2024
Q3 2023 Sep 30, 2022 ($16.98M) Nov 2, 2023
Q2 2023 Jun 30, 2022 ($16.94M) Aug 3, 2023
Q1 2023 Mar 31, 2022 ($18.51M) May 4, 2023
Q3 2022 Sep 30, 2021 ($17.23M) Nov 10, 2022
Q2 2022 Jun 30, 2021 ($45.22M) Aug 11, 2022
Q1 2022 Mar 31, 2021 ($13.85M) May 16, 2022